美股市场个股详情
ASND Ascendis Pharma A/S
- 129.810
- +7.170+5.85%
收盘价 11/22 16:00 (美东)
- 129.810
- 0.0000.00%
盘后 20:01 (美东)
77.57亿总市值-16614市盈率TTM
130.275最高价122.640最低价64.00万股成交量124.220今开122.640昨收8238.21万成交额1.08%换手率亏损市盈率(静)5976.04万总股本161.00052周最高-76.09市净率77.00亿流通值90.13052周最低--股息TTM5931.98万流通股183.980历史最高--股息率TTM6.23%振幅11.920历史最低128.721平均价1股每手
关于Ascendis Pharma A/S公司
Ascendis Pharma AS是一家生物制药公司。该公司利用其 Transcon 技术开发原药疗法，以满足大型市场未得到满足的医疗需求。该公司的产品线包括 Transcon 生长激素、Transconpeptides、Transcon PTH、Transcon CNP 等。该公司在北美、中国和欧洲开展业务，大部分收入来自北美。
公司介绍
公司代码ASND
公司名称Ascendis Pharma A/S
上市日期2015/01/28
发行价格18.00
成立日期2006
CEOMr. Jan Moller Mikkelsen
所属市场纳斯达克
员工数量879
证券类型存托凭证
ADS转换比例1.0 : 1.0
年结日12-31
公司地址Tuborg Boulevard 12
城市Hellerup
省份首都地区
国家丹麦
邮编2900
电话45-70-22-22-44
董事高管
- 姓名
- 职务
- 年薪
- Jan Moller Mikkelsen
- President, Chief Executive Officer and Director
- --
- Scott T Smith
- Executive Vice President and Chief Financial Officer
- --
- Camilla Harder Hartvig
- Executive Vice President and Global Chief Commercial Officer
- --
- Lotte Sonderbjerg
- Executive Vice President and Chief Administrative Officer
- --
- Michael Wolff Jensen
- Executive Vice President and Chief Legal Officer
- --
- Peter Rasmussen
- Vice President, Finance and Principal Accounting Officer
- --
- Dr. Kennett Sprogoe, PhD
- Executive Vice President and Head of Innovation and Research
- --
- Dr. Stina Singel, M.D.
- Executive Vice President and Head of Clinical Development, Oncology
- --
- Flemming Steen Jensen
- Executive Vice President, Product Supply and Quality
- --
- Dr. Albert Cha, M.D.,PhD
- Chairman of the Board
- --
- William Carl Fairey
- Independent Director
- --
- Lisa Bright
- Independent Director
- --
- Lars Holtug
- Independent Director
- --
- Siham Imani
- Independent Director
- --
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据